Boston, May 01, 2024 (GLOBE NEWSWIRE) -- Amwell® (NYSE: AMWL) a small-cap, growth healthcare company and a leading provider of healthcare software as a service, today announced financial results for the first quarter ended March 31, 2024. Visit Amwell’s investor relations website at investors.amwell.com to view the first quarter 2024 earnings report.
The company will host a conference call to discuss its financial results today at 5 p.m. ET, Wednesday, May 1. The call can be accessed via a live audio webcast at investors.amwell.com or by dialing 1-888-510-2008 for U.S. participants or 1-646-960-0306 for international participants, referencing conference ID #7830032. A replay of the call will be available via webcast shortly after the completion of the call, at the same web link.
About Amwell
Amwell is a leading hybrid care enablement platform in the United States and globally, connecting and enabling providers, payers, patients, and innovators to deliver greater access to more affordable, higher quality care. Amwell believes that hybrid care delivery will transform healthcare. We offer a single, comprehensive platform to support all digital health needs from urgent to acute and post-acute care, as well as chronic care management and healthy living. With nearly two decades of experience, Amwell powers the digital care of more than 50 health plans, which collectively represent more than 100 million covered lives, and many of the nation’s largest health systems. For more information, please visit https://business.amwell.com/.
American Well, Amwell, Converge, SilverCloud and Carepoints are registered trademarks or trademarks of American Well Corporation in the United States and other countries. All other trademarks used herein are the property of their respective owners.
Last Trade: | US$10.97 |
Daily Change: | 0.68 6.61 |
Daily Volume: | 38,601 |
Market Cap: | US$149.960M |
January 15, 2025 December 18, 2024 October 30, 2024 October 08, 2024 July 31, 2024 |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load